JPRN-UMIN000027050已完成未知
The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy - The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 85years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Had received the treatment, including IVIg, plasma exchange, or steroid within past three months 2. Has past history of hematological malignancy such as multiple myeloma, Waldenstroms macroglobulinemia, amyloidosis, and lymphoma 3. Had received some sort of immunosuppressive therapy within past six months
研究者
相似试验
已完成
2 期
The Evaluation of Efficacy and Safety of Rituximab (Genetical Recombination) in Refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Patients with Immunoglobulin G4 (IgG4) Autoantibodies in the Exploratory Clinical TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-UMIN000035753agoya University Hospital27
已完成
2 期
RECIPE TrialChronic Inflammatory Demyelinating PolyneuropathyJPRN-jRCT2041180037Iijima Masahiro25
已完成
2 期
Rituximab in treatment of Rheumatoid arthritis in Indian patientsCTRI/2017/08/009321CENTER FOR RHEUMATIC DISEASES60
进行中（未招募）
不适用
EVALUATION OF CLINICAL RESPONSE TO RITUXIMAB TREATMENT IN PATIENTS WITH ACQUIRED AUTOIMMUNE RECURRENT THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) - RITUXIMAB IN RECURRENT TTPMedDRA version: 9.1Level: LLTClassification code 10037562THROMBOTIC THROMBOCYTOPENIC PURPURAEUCTR2010-018794-38-ITFONDAZIONE IRCCS CA` GRANDA OSPEDALE MAGGIORE POLICLINICO DI MILANO
进行中（未招募）
不适用
Evaluación de la Eficacia de Rituximab en pacientes con Artritis Reumatoide a través de la medición, por Resonancia Magnética de Mano, de los parámetros clínicos de la enfermedad. Estudio RESONAR.Efficacy of rituximab in patients with Rheumatoid Arthritis, by measurement of disease parameters through magnetic resonance of the hand. RESONAR study.Pacientes con artritis reumatoide (AR) activa refractarios a uno o más fármacos antiTNF (definido por un DAS28>3,2).MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritisEUCTR2008-002381-55-ESROCHE FARMA, S.A.